Is methylene blue an approved medicine or a dietary supplement?

Methylene blue (methylthioninium chloride) is an approved, prescription medicine with a clearly defined indication: the treatment of acquired methemoglobinemia (in the USA since 2016 as PROVAYBLUE). Its use as a cognitive enhancer for healthy people is not an approved area of application. Products circulating online fall into a regulatory gray area and cannot be classified as a proven nootropic.

Does methylene blue really make you smarter or more capable?

This is not robustly established. There is a plausible mitochondrial mechanism and positive animal data, but the human studies are small and mainly show altered brain activity on imaging, not a robust improvement in everyday performance. Moreover, a molecule related to methylene blue missed its targets in large Alzheimer's trials. The advertising promises are assertions, not proof of effect in healthy people.

Why is methylene blue considered risky?

Two points stand out. First, it is a reversible MAO-A inhibitor and, together with antidepressants (SSRIs/SNRIs/MAO inhibitors) or opioids, can trigger a potentially fatal serotonin syndrome, which is why the prescribing information carries a Boxed Warning. Second, it is contraindicated in people with G6PD deficiency, as it can cause severe hemolysis. Medical clarification is therefore essential.

Nootropic & Mitochondria7 min readLast reviewed: June 2026

Methylene Blue: Brain-Boost or Hype? An Honest Assessment

Methylene blue (methylthioninium chloride) is not a new miracle agent but a synthetic dye from the 19th century that plays a remarkable dual role: an approved emergency medicine on the one hand, and a star of the biohacking scene on the other. On social media, the deep-blue liquid is advertised as a “brain-boost” for more energy, focus and mitochondrial performance. The cell-biology theory behind this is genuinely interesting and well described. The decisive question, however, is how much of it is established for cognition in humans, and how serious the known risks are. This article puts things in perspective, honestly and without hype, and does not replace medical advice.

Machine-assisted translation. The German original is the authoritative version.

Key points

Methylene blue is a drug substance more than 100 years old: today approved as an antidote against acquired methemoglobinemia, not as a nootropic.
The mitochondrial mechanism (electron cycling) is plausible but established predominantly in cell and animal models and is strongly dose-dependent (hormesis).
The human evidence for cognitive enhancement is thin: the central study was small (n=28) and showed only imaging signals; a related molecule failed in Phase 3 Alzheimer's trials.
Serious risks exist: a Boxed Warning for serotonin syndrome (MAO-A inhibition) and a contraindication in G6PD deficiency.
Hype and the evidence diverge; in matters of metabolism or hormones, medical clarification is required.

What is methylene blue, and where does it come from?

Methylene blue was first synthesized in 1876, making it one of the oldest industrially produced dyes of all. As early as the late 19th century, the substance was used in histology to stain cells and pathogens. In the late 1880s, Paul Ehrlich recognized that it could selectively stain malaria pathogens (plasmodia), and in 1891 methylene blue became the very first fully synthetic active substance ever used against malaria in humans. It remained in use as an antimalarial until the mid-20th century, before being displaced by more modern substances.

Today, methylene blue has a clearly defined, FDA-approved medical area of use: the treatment of acquired methemoglobinemia, a form of poisoning in which the blood can no longer transport oxygen properly. As an antidote it acts here as a redox agent that restores the function of the damaged blood pigment. This application takes place clinically and under supervision. The leap from this narrowly circumscribed emergency indication to a freely marketed “nootropic” for healthy people is large and should not be underestimated.

First synthesized in 1876; originally a textile and laboratory dye
1891: first fully synthetic antimalarial agent used in humans (Ehrlich/Guttmann)
Current approval (USA, since 2016 as PROVAYBLUE): acquired methemoglobinemia
As an antidote, a clinically supervised redox agent, not a lifestyle product

The mitochondrial mechanism: the plausible theory

The biohacking scene's enthusiasm draws on cell biology. Methylene blue can act as a so-called electron cycler in the mitochondrial respiratory chain: it takes up electrons from NADH and passes them on to cytochrome c oxidase (Complex IV). In theory, it can thereby bypass impaired sites of the respiratory chain (Complexes I–III) and so support cellular energy production (ATP) and oxygen consumption. In cell-culture and animal models it has been described that low doses can increase oxygen consumption and ATP production.

The key term here is hormesis: the effects are dose-dependent and reverse. What is meant to stimulate the mitochondria at low levels does exactly the opposite at higher levels and can disrupt the respiratory chain and become toxic. It is precisely this U-shaped dose–response curve that makes the substance tricky and is a central reason why experimenting on one's own without medical supervision is problematic. This mechanism is established predominantly in preclinical systems (cells, animals). A plausible mechanism does not automatically translate into a noticeable benefit for healthy people.

Can support the respiratory chain as an electron cycler (NADH → Complex IV)
Increased ATP production and O2 consumption, mainly in cell and animal models
Hormesis: stimulating at low levels, potentially damaging at high levels (U-curve)
Mechanism is plausible, but mechanism is not the same as human benefit

What research in humans actually shows

Here the gap between promise and proof becomes visible. A frequently cited randomized, double-blind, placebo-controlled study (Rodriguez et al., Brain Imaging and Behavior, 2017) investigated a single dose of methylene blue in just 28 healthy adults. Using functional imaging (fMRI) it found altered brain activity and stronger resting-state connectivity in memory and perception regions. That is an interesting signal, but: it is a very small sample, a single dose, and above all imaging data, not robust improvements in measurable everyday performance. The authors themselves name these limitations.

Even more telling is the major pharmaceutical development: a molecule related to methylene blue (LMTX/TRx0237, leuco-methylthioninium) was tested against Alzheimer's in large-scale Phase 3 trials. These trials missed their primary endpoints. When an optimized, heavily financed variant shows no convincing cognitive benefit in careful trials, that is a clear warning sign against simple “brain-boost” narratives. Bottom line on the evidence: animal data and mechanism are encouraging, but solid human evidence for cognitive enhancement in healthy people is so far lacking.

Central human study (2017): only n=28, single dose, fMRI signal rather than performance proof
An imaging change is not proof of better everyday cognition
Related molecule (LMTX/TRx0237) missed Phase 3 endpoints in Alzheimer's
A large divide: strong animal data, thin and inconsistent human data

Risks and serious limits

The risks are not a side note. Methylene blue is a potent, reversible inhibitor of monoamine oxidase A (MAO-A). In combination with serotonergic medications, this can trigger a life-threatening serotonin syndrome. The FDA prescribing information carries a Boxed Warning on this: concurrent use with SSRIs, SNRIs, MAO inhibitors and opioids should be avoided. Anyone taking antidepressants or certain pain or migraine medications is exposed here to a real, potentially fatal risk. This concerns a very large group of people.

Another hard limit is glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency), a widespread genetic enzyme defect. In these individuals, methylene blue is contraindicated according to the prescribing information, because it can trigger severe hemolysis (breakdown of red blood cells) and anemia. Many of those affected are unaware of their deficiency. Added to this are questions of quality and purity: only pharmaceutical-grade material is intended for human use; industrial dye products may contain heavy metals and contaminants. For all these reasons, the use of such substances belongs in medical hands; especially in matters of metabolism or hormones, prior medical clarification is strongly advised.

Reversible MAO-A inhibitor: Boxed Warning for serotonin syndrome
Avoid the dangerous combination with SSRIs/SNRIs/MAO inhibitors/opioids
Contraindicated in G6PD deficiency (risk of severe hemolysis)
Industrial dye products may contain contaminants/heavy metals

Putting the hype in perspective

Methylene blue is an instructive example of how genuine science turns into marketing. The building blocks are real: a long pharmaceutical history, a plausible mitochondrial mechanism, a few interesting imaging findings. From this, however, the online world constructs a salvation narrative that runs ahead of the evidence. Claims such as “more energy,” “sharper focus” or “anti-aging for the brain” are widespread in the community as assertions, not as established effects in healthy people.

Viewed soberly, methylene blue is an unfavorable choice for a layperson's self-experiment: a narrow therapeutic window (hormesis), serious interactions and a relevant genetic contraindication stand against so-far thin human evidence for cognition. This does not make it a “scandal substance,” but a serious drug substance with a clearly defined medical place and an overrated lifestyle role. Anyone informing themselves should know the difference between an approved antidote and a proven nootropic.

Real science is compressed into an exaggerated salvation narrative
Community promises are assertions, not proof of effect in healthy people
The risk-benefit profile argues against layperson self-experiments
An approved antidote ≠ a proven cognitive enhancer

Related substance profiles

MOTS-c

A mitochondrially encoded peptide — an "exercise mimetic" of research, not approved.

SS-31 (Elamipretid)

A cardiolipin-stabilizing mitochondrial peptide — approved in the USA for Barth syndrome in 2025.

Humanin

Mitochondria-derived 24-amino-acid peptide from neuro- and longevity research — experimental, not approved.

Frequently asked questions

Is methylene blue an approved medicine or a dietary supplement?: Methylene blue (methylthioninium chloride) is an approved, prescription medicine with a clearly defined indication: the treatment of acquired methemoglobinemia (in the USA since 2016 as PROVAYBLUE). Its use as a cognitive enhancer for healthy people is not an approved area of application. Products circulating online fall into a regulatory gray area and cannot be classified as a proven nootropic.
Does methylene blue really make you smarter or more capable?: This is not robustly established. There is a plausible mitochondrial mechanism and positive animal data, but the human studies are small and mainly show altered brain activity on imaging, not a robust improvement in everyday performance. Moreover, a molecule related to methylene blue missed its targets in large Alzheimer's trials. The advertising promises are assertions, not proof of effect in healthy people.
Why is methylene blue considered risky?: Two points stand out. First, it is a reversible MAO-A inhibitor and, together with antidepressants (SSRIs/SNRIs/MAO inhibitors) or opioids, can trigger a potentially fatal serotonin syndrome, which is why the prescribing information carries a Boxed Warning. Second, it is contraindicated in people with G6PD deficiency, as it can cause severe hemolysis. Medical clarification is therefore essential.

Sources

This article is for information and education only. It does not replace medical advice and deliberately contains no dosing, usage or sourcing information.

← All guide articles